ReviewFrontiers in immunology2023
Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 48 citations in OpenAlex.
- Microbiota-gut-brain axis and bile acids-driven neuromodulation.Neural regeneration research · 2026Article
- Underestimated and Overlooked Factors in PBC Progression: Bacterial and Fungal Infections.International journal of molecular sciences · 2026Review
- Primary Biliary Cholangitis Pathogenesis: A Pathophysiology-Based Narrative Review.International journal of molecular sciences · 2026Review
- Systemic inflammatory response index: a novel predictor for cardiovascular disease risk in patients with primary biliary cholangitis.European journal of medical research · 2025Article
- Autoantibodies in Primary Biliary Cholangitis: From Classical Markers to Emerging Targets.Journal of clinical medicine · 2025Review
- Microbiome and gut-liver interactions: From mechanisms to therapies.World journal of gastroenterology · 2025Review
- Lymphocyte-to-Monocyte Ratio as a Predictor of Recompensation in Patients With Decompensated Primary Biliary Cholangitis.Alimentary pharmacology & therapeutics · 2025Article
- Review
- Identification of secretory protein related biomarkers for primary biliary cholangitis based on machine learning and experimental validation.Open life sciences · 2025Article
- Exploring the Pathogenesis of Autoimmune Liver Diseases from the Heterogeneity of Target Cells.Journal of clinical and translational hepatology · 2024Review
- Progress in the Management of Patients with Cholestatic Liver Disease: Where Are We and Where Are We Going?Journal of clinical and translational hepatology · 2024Review
- Distinct signatures of gut microbiota and metabolites in primary biliary cholangitis with poor biochemical response after ursodeoxycholic acid treatment.Cell & bioscience · 2024Article
- JCAD, a new potential therapeutic target in cholestatic liver disease.Clinical and molecular hepatology · 2024Article
- High C-reactive protein-to-albumin ratio levels are associated with osteoporosis in patients with primary biliary cholangitis.Frontiers in endocrinology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary biliary cirrhosis (PBC) is a chronic cholestatic immune liver disease characterized by persistent cholestasis, interlobular bile duct damage, portal inflammation, liver fibrosis, eventual cirrhosis, and death. Existing clinical and animal studies have made a good progress in bile acid metabolism, intestinal flora disorder inflammatory response, bile duct cell damage, and autoimmune response mechanisms. However, the pathogenesis of PBC has not been clearly elucidated. We focus on the pathological mechanism and new drug research and development of PBC in clinical and laboratory in the recent 20 years, to discuss the latest understanding of the pathological mechanism, treatment options, and drug discovery of PBC. Current clinical treatment mode and symptomatic drug support obviously cannot meet the urgent demand of patients with PBC, especially for the patients who do not respond to the current treatment drugs. New treatment methods are urgently needed. Drug candidates targeting reported targets or signals of PBC are emerging, albeit with some success and some failure. Single-target drugs cannot achieve ideal clinical efficacy. Multitarget drugs are the trend of future research and development of PBC drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.